Inflammation and Cardiovascular Disease: The Future
Standard
Inflammation and Cardiovascular Disease: The Future. / Arnold, Natalie; Lechner, Katharina; Waldeyer, Christoph; Shapiro, Michael D; Koenig, Wolfgang.
In: EUR CARDIOL REV, Vol. 16, e20, 02.2021.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Inflammation and Cardiovascular Disease: The Future
AU - Arnold, Natalie
AU - Lechner, Katharina
AU - Waldeyer, Christoph
AU - Shapiro, Michael D
AU - Koenig, Wolfgang
N1 - Copyright © 2021, Radcliffe Cardiology.
PY - 2021/2
Y1 - 2021/2
N2 - Despite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or systemic circulation, which are driven in a large part by modified lipoproteins but subsequently trigger a hypercoagulable state, are a hallmark of atherosclerotic cardiovascular disease and, in particular, its clinical complications. Extending conventional guideline-based clinical risk stratification algorithms by adding biomarkers of inflammation may refine phenotypic screening, improve risk stratification and guide treatment eligibility in cardiovascular disease prevention. The integration of interventions aimed at lowering the inflammatory burden, alone or in combination with aggressive lipid-modifying or even antithrombotic agents, for those at high cardiovascular risk may hold the potential to reduce the still substantial burden of cardiometabolic disease. This review provides perspectives on future clinical research in atherosclerosis addressing the tight interplay between inflammation, lipid metabolism and thrombosis, and its translation into clinical practice.
AB - Despite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or systemic circulation, which are driven in a large part by modified lipoproteins but subsequently trigger a hypercoagulable state, are a hallmark of atherosclerotic cardiovascular disease and, in particular, its clinical complications. Extending conventional guideline-based clinical risk stratification algorithms by adding biomarkers of inflammation may refine phenotypic screening, improve risk stratification and guide treatment eligibility in cardiovascular disease prevention. The integration of interventions aimed at lowering the inflammatory burden, alone or in combination with aggressive lipid-modifying or even antithrombotic agents, for those at high cardiovascular risk may hold the potential to reduce the still substantial burden of cardiometabolic disease. This review provides perspectives on future clinical research in atherosclerosis addressing the tight interplay between inflammation, lipid metabolism and thrombosis, and its translation into clinical practice.
U2 - 10.15420/ecr.2020.50
DO - 10.15420/ecr.2020.50
M3 - SCORING: Review article
C2 - 34093741
VL - 16
JO - EUR CARDIOL REV
JF - EUR CARDIOL REV
SN - 1758-3756
M1 - e20
ER -